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clinical care (doctor-patient relationship, competence 
of nursing staff, etc.); 2) Satisfaction with physical 
surroundings (medical facilities, organisational structure,
etc.); 3) Satisfaction with clinical outcomes (result of
treatment, impairment due to side effects, etc.) In the
focus groups patients reported that analgesics and their
application forms have an impact on acceptance, com-
pliance, and on several areas of life such as sleep and life
style. CONCLUSIONS: The results of the focus groups
support the assumption, that at least one further dimen-
sion of patient’s satisfaction exists: satisfaction with
medical treatment. This aspect has not yet been taken up
by theoretical or empirical research. Due to this, world
wide there is no instrument for recording this dimension
today. The need to develop a new questionnaire to estab-
lish patients level of acceptance and satisfaction with 
their medication was speciﬁed and suggestions for a 4-
dimensional model of patient’s satisfaction were made.
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OBJECTIVES: A lot of attention is focused on the
outcome effectiveness of substance abuse treatment. The
usual method of assessing outcomes is by contacting
clients after treatment and querying them on recovery-
related behaviors and on drug/alcohol use. Since
researchers are not always able to contact every client
after treatment, the issue of response bias is important.
Missing data is MAR, and thus ignorable, if differences
between respondents and nonrespondents can be charac-
terized by variables that are measured for both groups.
The objective of this research is to illuminate this issue by
using data collected from a U.S. treatment population and
to discuss statistical methods for correcting response bias.
METHODS: The data were collected from treatment
records and follow-up interviews of clients completing
substance abuse treatment at a facility in the U.S. Appro-
priate consent was obtained. Each client contacted was
administered a questionnaire. Eighty-eight (44.9%) com-
pleted the questionnaire; 102 (52.4%) could not be con-
tacted. Since the treatment records for the responders and
nonresponders were available, information was extracted
on variables related to treatment outcomes so that statis-
tical analysis could be conducted. RESULTS: No differ-
ences were found between responders and nonresponders
for most variables. Variables measuring demographics,
family support/structure, criminality/truancy, psychologi-
cal comorbidities, treatment attributes, and drug use were
not different. Variables with statistically signiﬁcant dif-
ferences were: “number of months at current residence”
(t = 2.12 p = .037) and the proportion “holding jobs”
(difference in proportions = .182; 95% CI = .043 to .321).
CONCLUSIONS: Missing data are not MAR, and thus
not ignorable, when missing variables are the same as or
related to variables that determine outcomes. In this case
“number of months at current residence” and “holding a
job” may predict treatment success. If this is true, some
method of control must be used. Weighting adjustments
such as post-stratiﬁcation and likelihood-based methods
are considered. Since the variables that predict treatment
outcomes are not fully understood, it is difﬁcult to be
certain MAR criteria are met.
METHODOLOGY ISSUES—Economic Study Issues
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OBJECTIVES: This paper presents a model based on real
option analysis for the valuation of R&D in the phar-
maceutical sector both for start-up ventures as well as big
conglomerates. We derive a formal compound option
model to value New Drug Applications (NDA) and show
the valuable contribution of real option analysis com-
pared to conventional DCF-analysis. METHODS: The
key understanding is that R&D projects of NDAs can be
seen as compound options. The growth option frame-
work looks at pharmaceutical investment projects as a
sequence of options, which differs from a conventional
DCF-analysis by incorporating the possibility to stop 
the project when a subsequent phase is not valuable
(abandon the option), and only continues with the project
(exercising the option) when it is valuable. Traditional
valuation techniques as DCF-analysis fail in valuing 
innovative companies because most of the value of R&D
projects is embedded in unexercised real options whose
future value is uncertain at this moment. If one considers
a company as a portfolio of real options, one can value
the projects or the company based on a compound option
model. RESULTS: The compound option model reveals
that real option analysis can better incorporate the value
of a NDA than conventional DCF-analysis would reveal.
Real option analysis will better reﬂect the fundamental
value of the project or of the company, which cannot be
captured by DCF-analysis. CONCLUSION: The paper
presents a new methodology for valuing R&D of 
pharmaceutical companies based on compound option
models.
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OBJECTIVE: Develop methodology to create a more
globally informative, CE-based “valuation” that is useful
